Antisense Video
Antisense Therapy and the creation of the SOD1 protein.May 22, 2012
Visit sam-fernandez.com. A project I created for the Muscular Dystrophy Association. It deals with the concept of Antisense therapy - in which scientist kill targeted strands of RNA that are responsible for the creation of the SOD1 protein. The animation was created before the script and voice over, so there is a bit of a disconnect between what's happening on the screen and what's being said. This is not a finished product. It was put on hold indefinately and never fully realized. The animation itself was shown during the Jerry Lewis 2010 telethon, which is broadcast nationally, during several of the research updates.
Antisense EngineeringMay 20, 2012
Biochemistry Final. Antisense Engineering is a method of silencing genes. A rollicking nucleotide-ripper with plenty of double helix rotations and biology major melodrama. Soundtrack: Audrey's Dad.
Bidirectional Transcription and Antisense Repression of ataxin-7Nov 10, 2011
CAG repeat expansions in the ataxin-7 gene cause the neurodegenerative disorder SCA7. Al La Spada and colleagues have discovered that ataxin-7 expression is governed by SCAANT1, an antisense non-coding RNA transcribed from an adjacent alternative promoter. Transactivation of SCAANT1 is linked to repression of ataxin-7 transcription and chromatin remodeling, suggesting that altered epigenetic regulation may contribute to disease pathology. Read more in Sopher et al., Neuron 70(6).
Shadowcast - AntisenseMar 16, 2012
Album: Near Life Experience (2003) Lyrics: the final showdown... I don't know where to go... I don't know where to go by now... to let my anger grow to let my hatred flow somehow 'cause when I put on the news, each day at night & see all the conflicts that may or even will collide there is no more excuse for our self-abuse all these goddamn things - I even feel amused come on, take it on by now, this bitter role of playing god somehow or even satan's pole double moral, the freedom choral our mind-expanse, your ignorance! I'm feeling somehow better now, after all the fury's out & nothing could cure my damn agonies I'm feeling somehow lighter now, after all the pain's cried out & nothing could build more stupidities disastrous & mournful, adventurous & harmful this is how the story goes but then again I decide that my dreams should not hide & no-one ever knows & then I realise one thing - that we are killing ourselves 'cause our greed is leading us to our own graves "wise" decisions & blind superstitions hatespin facility & the deathroll fatality to venus & black or just a strange little pill new conflict dimension & some more reasons until the hate based machinery, a cold subsidarity is starting its fucking tech-raging clarity
Leinender - Sight of the Unseen (Antisense remix)Nov 26, 2011
Leinender - Sight of the Unseen (Antisense remix) [Techno]
Kreidezeit 31: Antisense-TechnikMar 20, 2012
In dieser Folge der Kreidezeit erklären wir, wie Wissenschaftler die Expression unerwünschter Enzyme verhindern können. Ein Service von www.biotechnologie.de.
PALOMAR - Absolutely MiserableMay 03, 2012
Absolutely Miserable from the PALOMAR album, Sense & Antisense, released on 1/24/12. The album is available on Itunes and at palomartheband.com . Like us at https Sarah Brockett - bass, vocals Dale W Miller - drum kit Christina Prostano - guitar, keyboards, vocals Rachel Warren - vocals, guitar
TEEN DERM from ISISPHARMAMar 28, 2012
natural-herbs-market.com Pioneering antisense drug discovery We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity. With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. We license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. Since 2007, our partnerships have generated an aggregate of more than $880 million in payments from licensing fees, equity purchase payments, milestone payments and research and development funding. In addition, for our current partnered drugs we have the potential to earn more than $3.5 billion in future milestone payments. We also will share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, and/or royalty arrangements. Furthermore, as an innovator in RNA-based drug discovery and development, we have designed and executed a patent ...
Lanoderm from Isis pharma.flvMar 28, 2012
www.natural-biocare.com Pioneering antisense drug discovery We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity. With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. We license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. Since 2007, our partnerships have generated an aggregate of more than $880 million in payments from licensing fees, equity purchase payments, milestone payments and research and development funding. In addition, for our current partnered drugs we have the potential to earn more than $3.5 billion in future milestone payments. We also will share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, and/or royalty arrangements. Furthermore, as an innovator in RNA-based drug discovery and development, we have designed and executed a patent ...
Dance your Ph D 2011.mp4May 14, 2012
Inzending voor de Science Dance Your Ph.D contest 2011 Via een dans wordt de toepassing van Exon Skipping in de behandeling van Duchenne patienten uitgebeeld door onderzoekers van de afdeling Humane Genetica van het Leids Universitair Medisch Centrum (LUMC).
